Focal therapy for prostate cancer.
Focal ablative therapy
Prostate cancer
Journal
Abdominal radiology (New York)
ISSN: 2366-0058
Titre abrégé: Abdom Radiol (NY)
Pays: United States
ID NLM: 101674571
Informations de publication
Date de publication:
20 Aug 2024
20 Aug 2024
Historique:
received:
31
03
2024
accepted:
30
06
2024
revised:
28
06
2024
medline:
20
8
2024
pubmed:
20
8
2024
entrez:
20
8
2024
Statut:
aheadofprint
Résumé
Traditional treatments for localized prostate cancer include radical prostatectomy or radiation therapy but pose challenges due to treatment related side effects, namely erectile dysfunction and urinary incontinence. In recent years, focal therapy has emerged as a viable treatment option for localized low-intermediate risk prostate cancer in carefully selected patients. Short and medium-term studies show acceptable cancer control outcomes and reduced morbidity when comparing focal therapy to whole gland treatment for prostate cancer, however there is paucity of long-term studies. Here we review focal ablative therapies commonly used, discuss the role of imaging in monitoring treatment, and summarize oncologic outcomes based on studies to date.
Identifiants
pubmed: 39162800
doi: 10.1007/s00261-024-04482-7
pii: 10.1007/s00261-024-04482-7
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Pinsky PF, Parnes H. Screening for Prostate Cancer. N Engl J Med 2023; 388(15):1405–1414.
pubmed: 37043655
doi: 10.1056/NEJMcp2209151
Mohler JL, Antonarakis ES, Armstrong AJ, D’Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington TA, Higano CS et al. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2019; 17(5):479–505.
pubmed: 31085757
doi: 10.6004/jnccn.2019.0023
Pierorazio PM, Walsh PC, Partin AW, Epstein JI. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int 2013; 111(5):753–760.
pubmed: 23464824
pmcid: 3978145
doi: 10.1111/j.1464-410X.2012.11611.x
Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL, Martin RM, Young GJ, Walsh EI, Bryant RJ et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023; 388(17):1547–1558.
pubmed: 36912538
doi: 10.1056/NEJMoa2214122
Arcot R, Polascik TJ. Evolution of Focal Therapy in Prostate Cancer: Past, Present, and Future. Urol Clin North Am 2022; 49(1):129–152.
pubmed: 34776047
doi: 10.1016/j.ucl.2021.07.011
Karavitakis M, Winkler M, Abel P, Livni N, Beckley I, Ahmed HU. Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: implications for focal therapy. Prostate Cancer Prostatic Dis 2011; 14(1):46–52.
pubmed: 20498680
doi: 10.1038/pcan.2010.16
Eastham JA, Boorjian SA, Kirkby E. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline. J Urol 2022; 208(3):505–507.
pubmed: 35830561
doi: 10.1097/JU.0000000000002854
Ahdoot M, Lebastchi AH, Turkbey B, Wood B, Pinto PA. Contemporary treatments in prostate cancer focal therapy. Curr Opin Oncol 2019; 31(3):200–206.
pubmed: 30865133
pmcid: 6465079
doi: 10.1097/CCO.0000000000000515
Tan N, Margolis DJ, Lu DY, King KG, Huang J, Reiter RE, Raman SS. Characteristics of Detected and Missed Prostate Cancer Foci on 3-T Multiparametric MRI Using an Endorectal Coil Correlated With Whole-Mount Thin-Section Histopathology. AJR Am J Roentgenol 2015; 205(1):W87-92.
pubmed: 26102423
doi: 10.2214/AJR.14.13285
Tay KJ, Scheltema MJ, Ahmed HU, Barret E, Coleman JA, Dominguez-Escrig J, Ghai S, Huang J, Jones JS, Klotz LH et al. Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus Project. Prostate Cancer Prostatic Dis 2017; 20(3):294–299.
pubmed: 28349978
doi: 10.1038/pcan.2017.8
Lebastchi AH, George AK, Polascik TJ, Coleman J, de la Rosette J, Turkbey B, Wood BJ, Gorin MA, Sidana A, Ghai S et al. Standardized Nomenclature and Surveillance Methodologies After Focal Therapy and Partial Gland Ablation for Localized Prostate Cancer: An International Multidisciplinary Consensus. Eur Urol 2020; 78(3):371–378.
pubmed: 32532513
pmcid: 8966411
doi: 10.1016/j.eururo.2020.05.018
Tan WP, Rastinehad AR, Klotz L, Carroll PR, Emberton M, Feller JF, George AK, Gill IS, Gupta RT, Katz AE et al. Utilization of focal therapy for patients discontinuing active surveillance of prostate cancer: Recommendations of an international Delphi consensus. Urol Oncol 2021; 39(11):781 e717-781 e724.
pmcid: 8654321
doi: 10.1016/j.urolonc.2021.01.027
Alabousi M, Ghai S, Haider MA. MRI-guided Minimally Invasive Focal Therapies for Prostate Cancer. Radiology 2023; 309(3):e230431.
pubmed: 38051187
doi: 10.1148/radiol.230431
Ehdaie B, Tempany CM, Holland F, Sjoberg DD, Kibel AS, Trinh QD, Durack JC, Akin O, Vickers AJ, Scardino PT et al. MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study. Lancet Oncol 2022; 23(7):910–918.
pubmed: 35714666
pmcid: 9400094
doi: 10.1016/S1470-2045(22)00251-0
Basso Dias A, Ghai S, Ortega C, Mirshahvalad SA, Perlis N, Berlin A, Avery L, Veit-Haibach P, van der Kwast T, Metser U. Impact of 18F-DCFPyL PET/MRI in Selecting Men With Low-/Intermediate-Risk Prostate Cancer for Focal Ablative Therapies. Clin Nucl Med 2023; 48(10):e462-e467.
pubmed: 37682613
doi: 10.1097/RLU.0000000000004819
Metser U, Ortega C, Perlis N, Lechtman E, Berlin A, Anconina R, Eshet Y, Chan R, Veit-Haibach P, van der Kwast TH et al. Detection of clinically significant prostate cancer with (18)F-DCFPyL PET/multiparametric MR. Eur J Nucl Med Mol Imaging 2021; 48(11):3702–3711.
pubmed: 33846845
doi: 10.1007/s00259-021-05355-7
Basso Dias A, Ghai S. Micro-Ultrasound: Current Role in Prostate Cancer Diagnosis and Future Possibilities. Cancers (Basel) 2023; 15(4).
Ghai S, Finelli A, Corr K, Chan R, Jokhu S, Li X, McCluskey S, Konukhova A, Hlasny E, van der Kwast TH et al. MRI-guided Focused Ultrasound Ablation for Localized Intermediate-Risk Prostate Cancer: Early Results of a Phase II Trial. Radiology 2021; 298(3):695–703.
pubmed: 33529137
doi: 10.1148/radiol.2021202717
Woodrum DA, Kawashima A, Gorny KR, Mynderse LA. Prostate cancer. state of the art imaging and focal treatment. Clin Radiol 2017; 72(8):665–679.
pubmed: 28385253
doi: 10.1016/j.crad.2017.02.010
Arcot R, Potts BA, Polascik TJ. Focal Cryoablation of Image-Localized Prostate Cancer. J Endourol 2021; 35(S2):S17-S23.
pubmed: 34499551
doi: 10.1089/end.2021.0411
Lodeizen O, de Bruin M, Eggener S, Crouzet S, Ghai S, Varkarakis I, Katz A, Dominguez-Escrig JL, Pahernik S, de Reijke T et al. Ablation energies for focal treatment of prostate cancer. World J Urol 2019; 37(3):409–418.
pubmed: 29943219
doi: 10.1007/s00345-018-2364-x
Shah TT, Arbel U, Foss S, Zachman A, Rodney S, Ahmed HU, Arya M. Modeling Cryotherapy Ice Ball Dimensions and Isotherms in a Novel Gel-based Model to Determine Optimal Cryo-needle Configurations and Settings for Potential Use in Clinical Practice. Urology 2016; 91:234–240.
pubmed: 26902833
doi: 10.1016/j.urology.2016.02.012
Shah TT, Ahmed H, Kanthabalan A, Lau B, Ghei M, Maraj B, Arya M. Focal cryotherapy of localized prostate cancer: a systematic review of the literature. Expert Rev Anticancer Ther 2014;14(11):1337–1347.
pubmed: 25367324
doi: 10.1586/14737140.2014.965687
Shah TT, Peters M, Eldred-Evans D, Miah S, Yap T, Faure-Walker NA, Hosking-Jervis F, Thomas B, Dudderidge T, Hindley RG et al. Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry. Eur Urol 2019; 76(1):98–105.
pubmed: 30638633
doi: 10.1016/j.eururo.2018.12.030
Napoli A, Alfieri G, Scipione R, Leonardi A, Fierro D, Panebianco V, De Nunzio C, Leonardo C, Catalano C. High-intensity focused ultrasound for prostate cancer. Expert Rev Med Devices 2020; 17(5):427–433.
pubmed: 32275187
doi: 10.1080/17434440.2020.1755258
Sundaram KM, Chang SS, Penson DF, Arora S. Therapeutic Ultrasound and Prostate Cancer. Semin Intervent Radiol 2017; 34(2):187–200.
pubmed: 28579687
pmcid: 5453783
doi: 10.1055/s-0037-1602710
Guillaumier S, Peters M, Arya M, Afzal N, Charman S, Dudderidge T, Hosking-Jervis F, Hindley RG, Lewi H, McCartan N et al. A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer. Eur Urol 2018; 74(4):422–429.
pubmed: 29960750
pmcid: 6156573
doi: 10.1016/j.eururo.2018.06.006
Schmid FA, Schindele D, Mortezavi A, Spitznagel T, Sulser T, Schostak M, Eberli D. Prospective multicentre study using high intensity focused ultrasound (HIFU) for the focal treatment of prostate cancer: Safety outcomes and complications. Urol Oncol 2020; 38(4):225–230.
pubmed: 31628038
doi: 10.1016/j.urolonc.2019.09.001
Klotz L, Pavlovich CP, Chin J, Hatiboglu G, Koch M, Penson D, Raman S, Oto A, Futterer J, Serrallach M et al. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer. J Urol 2021; 205(3):769–779.
pubmed: 33021440
doi: 10.1097/JU.0000000000001362
Nicoletti R, Alberti A, Castellani D, Yee CH, Zhang K, Poon DMC, Chiu PK, Campi R, Resta GR, Dibilio E et al. Oncological results and cancer control definition in focal therapy for Prostate Cancer: a systematic review. Prostate Cancer Prostatic Dis 2023.
Westin C, Chatterjee A, Ku E, Yousuf A, Wang S, Thomas S, Fan X, Eggener S, Karczmar G, Oto A. MRI Findings After MRI-Guided Focal Laser Ablation of Prostate Cancer. AJR Am J Roentgenol 2018; 211(3):595–604.
pubmed: 29995499
doi: 10.2214/AJR.17.19201
Walser E, Nance A, Ynalvez L, Yong S, Aoughsten JS, Eyzaguirre EJ, Williams SB. Focal Laser Ablation of Prostate Cancer: Results in 120 Patients with Low- to Intermediate-Risk Disease. J Vasc Interv Radiol 2019; 30(3):401–409 e402.
pubmed: 30819483
pmcid: 8503805
doi: 10.1016/j.jvir.2018.09.016
Mehralivand S, George AK, Hoang AN, Rais-Bahrami S, Rastinehad AR, Lebastchi AH, Ahdoot M, Siddiqui MM, Bloom J, Sidana A et al. MRI-guided focal laser ablation of prostate cancer: a prospective single-arm, single-center trial with 3 years of follow-up. Diagn Interv Radiol 2021; 27(3):394–400.
pubmed: 34003127
pmcid: 8136525
doi: 10.5152/dir.2021.20095
Blazevski A, Scheltema MJ, Amin A, Thompson JE, Lawrentschuk N, Stricker PD. Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment. BJU Int 2020; 125(3):369–378.
pubmed: 31725935
doi: 10.1111/bju.14951
van den Bos W, Scheltema MJ, Siriwardana AR, Kalsbeek AMF, Thompson JE, Ting F, Bohm M, Haynes AM, Shnier R, Delprado W et al. Focal irreversible electroporation as primary treatment for localized prostate cancer. BJU Int 2018; 121(5):716–724.
pubmed: 28796935
doi: 10.1111/bju.13983
Ting F, Tran M, Bohm M, Siriwardana A, Van Leeuwen PJ, Haynes AM, Delprado W, Shnier R, Stricker PD. Focal irreversible electroporation for prostate cancer: functional outcomes and short-term oncological control. Prostate Cancer Prostatic Dis 2016; 19(1):46–52.
pubmed: 26458959
doi: 10.1038/pcan.2015.47
Blazevski A, Scheltema MJ, Yuen B, Masand N, Nguyen TV, Delprado W, Shnier R, Haynes AM, Cusick T, Thompson J et al. Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort. Eur Urol Oncol 2020; 3(3):283–290.
pubmed: 31103721
doi: 10.1016/j.euo.2019.04.008
Faiella E, Santucci D, Vertulli D, Vergantino E, Vaccarino F, Perillo G, Beomonte Zobel B, Grasso RF. Irreversible Electroporation (IRE) for Prostate Cancer (PCa) Treatment: The State of the Art. J Pers Med 2024; 14(2).
Flegar L, Buerk B, Proschmann R, Propping S, Groeben C, Baunacke M, Herout R, Huber J, Thomas C, Borkowetz A. Vascular-targeted Photodynamic Therapy in Unilateral Low-risk Prostate Cancer in Germany: 2-yr Single-centre Experience in a Real-world Setting Compared with Radical Prostatectomy. Eur Urol Focus 2022; 8(1):121–127.
pubmed: 33602642
doi: 10.1016/j.euf.2021.01.018
Dickinson L, Ahmed HU, Hindley RG, McCartan N, Freeman A, Allen C, Emberton M, Kirkham AP. Prostate-specific antigen vs. magnetic resonance imaging parameters for assessing oncological outcomes after high intensity-focused ultrasound focal therapy for localized prostate cancer. Urol Oncol 2017; 35(1):30 e39-30 e15.
Huber PM, Afzal N, Arya M, Boxler S, Dudderidge T, Emberton M, Guillaumier S, Hindley RG, Hosking-Jervis F, Leemann L et al. Prostate Specific Antigen Criteria to Diagnose Failure of Cancer Control following Focal Therapy of Nonmetastatic Prostate Cancer Using High Intensity Focused Ultrasound. J Urol 2020; 203(4):734–742.
pubmed: 31928408
doi: 10.1097/JU.0000000000000747
Light A, Mayor N, Cullen E, Kirkham A, Padhani AR, Arya M, Bomers JGR, Dudderidge T, Ehdaie B, Freeman A et al. The Transatlantic Recommendations for Prostate Gland Evaluation with Magnetic Resonance Imaging After Focal Therapy (TARGET): A Systematic Review and International Consensus Recommendations. Eur Urol 2024.
Tokuda B, Yamada K, Takahata A, Fujihara A, Iwata T, Ukimura O, Yamada K. Time-course changes in multiparametric magnetic resonance imaging following focal cryotherapy for localized prostate cancer: Initial experience. Eur J Radiol 2023; 160:110714.
pubmed: 36738598
doi: 10.1016/j.ejrad.2023.110714
Giganti F, Dickinson L, Orczyk C, Haider A, Freeman A, Emberton M, Allen C, Moore CM. Prostate Imaging after Focal Ablation (PI-FAB): A Proposal for a Scoring System for Multiparametric MRI of the Prostate After Focal Therapy. Eur Urol Oncol 2023; 6(6):629–634.
pubmed: 37210343
doi: 10.1016/j.euo.2023.04.007
Ahn H, Hwang SI, Lee HJ, Kim SY, Cho JY, Lee H, Hong SK, Byun SS, Kim TM. Diagnostic performance of MRI for prediction of recurrent prostate cancer after high-intensity focused ultrasound: a systematic review and meta-analysis. Prostate Int 2023; 11(2):59–68.
pubmed: 37409098
doi: 10.1016/j.prnil.2022.12.004
Gelikman DG, Kenigsberg AP, Mee Law Y, Yilmaz EC, Harmon SA, Parikh SH, Hyman JA, Huth H, Koller CR, Nethala D et al. Evaluating Diagnostic Accuracy and Inter-reader Agreement of the Prostate Imaging After Focal Ablation Scoring System. Eur Urol Open Sci 2024; 62:74–80.
pubmed: 38468864
pmcid: 10925932
doi: 10.1016/j.euros.2024.02.012
Paxton M, Barbalat E, Perlis N, Menezes RJ, Gertner M, Dragas D, Haider MA, Finelli A, Trachtenberg J, Ghai S. Role of multiparametric MRI in long-term surveillance following focal laser ablation of prostate cancer. Br J Radiol 2022; 95(1131):20210414.
pubmed: 34324385
doi: 10.1259/bjr.20210414
Abreu-Gomez J, Haider M, Ghai S: Re: Francesco Giganti, Louise Dickinson, Clement Orczyk, et al. Prostate Imaging After Focal Ablation (PI-FAB): A Proposal for a Scoring System for Multiparametric MRI of the Prostate After Focal Therapy. Eur Urol Oncol. 2023;6:629–634. Eur Urol Oncol 2024; 7(1):169–170.
Heard JR, Naser-Tavakolian A, Nazmifar M, Ahdoot M. Focal prostate cancer therapy in the era of multiparametric MRI: a review of options and outcomes. Prostate Cancer Prostatic Dis 2023; 26(2):218–227.
pubmed: 35246609
doi: 10.1038/s41391-022-00501-0
Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL, Stroup AM et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 2013; 368(5):436–445.
pubmed: 23363497
pmcid: 3742365
doi: 10.1056/NEJMoa1209978
Stabile A, Orczyk C, Hosking-Jervis F, Giganti F, Arya M, Hindley RG, Dickinson L, Allen C, Punwani S, Jameson C et al. Medium-term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localized prostate cancer. BJU Int 2019; 124(3):431–440.
pubmed: 30753756
doi: 10.1111/bju.14710
Ghai S, Finelli A, Corr K, Lajkosz K, McCluskey S, Chan R, Gertner M, van der Kwast TH, Incze PF, Zlotta AR et al. MRI-guided Focused Ultrasound Focal Therapy for Intermediate-Risk Prostate Cancer: Final Results from a 2-year Phase II Clinical Trial. Radiology 2024; 310(3):e231473.
pubmed: 38441092
doi: 10.1148/radiol.231473
Hopstaken JS, Bomers JGR, Sedelaar MJP, Valerio M, Futterer JJ, Rovers MM. An Updated Systematic Review on Focal Therapy in Localized Prostate Cancer: What Has Changed over the Past 5 Years? Eur Urol 2022; 81(1):5–33.
pubmed: 34489140
doi: 10.1016/j.eururo.2021.08.005
Zhang K, Stricker P, Lohr M, Stehling M, Suberville M, Cussenot O, Lunelli L, Ng CF, Teoh J, Laguna P et al. A multi-center international study to evaluate the safety, functional and oncological outcomes of irreversible electroporation for the ablation of prostate cancer. Prostate Cancer Prostatic Dis 2024.
Scheltema MJ, Geboers B, Blazevski A, Doan P, Katelaris A, Agrawal S, Barreto D, Shnier R, Delprado W, Thompson JE et al. Median 5-year outcomes of primary focal irreversible electroporation for localised prostate cancer. BJU Int 2023; 131 Suppl 4:6–13.
pubmed: 36495481
doi: 10.1111/bju.15946
Noweski A, Roosen A, Lebdai S, Barret E, Emberton M, Benzaghou F, Apfelbeck M, Gaillac B, Gratzke C, Stief C et al. Medium-term Follow-up of Vascular-targeted Photodynamic Therapy of Localized Prostate Cancer Using TOOKAD Soluble WST-11 (Phase II Trials). Eur Urol Focus 2019; 5(6):1022–1028.
pubmed: 29661587
doi: 10.1016/j.euf.2018.04.003
van Son MJ, Peters M, Reddy D, Shah TT, Hosking-Jervis F, Robinson S, Lagendijk JJW, Mangar S, Dudderidge T, McCracken S et al. Conventional radical versus focal treatment for localised prostate cancer: a propensity score weighted comparison of 6-year tumour control. Prostate Cancer Prostatic Dis 2021; 24(4):1120–1128.
pubmed: 33934114
doi: 10.1038/s41391-021-00369-6
Shah TT, Reddy D, Peters M, Ball D, Kim NH, Gomez EG, Miah S, Evans DE, Guillaumier S, van Rossum PSN et al. Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study. Prostate Cancer Prostatic Dis 2021; 24(2):567–574.
pubmed: 33504940
doi: 10.1038/s41391-020-00315-y
Reddy D, Peters M, Shah TT, van Son M, Tanaka MB, Huber PM, Lomas D, Rakauskas A, Miah S, Eldred-Evans D et al. Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience. Eur Urol 2022; 81(4):407–413.
pubmed: 35123819
doi: 10.1016/j.eururo.2022.01.005
Nathan A, Ng A, Mitra A, Sooriakumaran P, Davda R, Patel S, Fricker M, Kelly J, Shaw G, Rajan P et al. Comparative Effectiveness Analyses of Salvage Prostatectomy and Salvage Radiotherapy Outcomes Following Focal or Whole-Gland Ablative Therapy (High-Intensity Focused Ultrasound, Cryotherapy or Electroporation) for Localised Prostate Cancer. Clin Oncol (R Coll Radiol) 2022; 34(1):e69-e78.
pubmed: 34740477
doi: 10.1016/j.clon.2021.10.012